Immunocore reports Phase 1 brenetafusp data: 56% disease control in checkpoint pre-treated melanoma

Immunocore Holdings plc

Brenetafusp monotherapy in 47 late-line cutaneous melanoma patients showed 56% DCR (4 PR, 16 SD) and 4.2 months median PFS in PRAME+ patients.
ctDNA molecular response in 42% of PRAME+ patients; trend for longer PFS/OS in molecular responders.
Combination with pembrolizumab well tolerated; 4/7 evaluable patients achieved disease control including 1 ongoing PR.
T cell fitness gene signature: high expression associated with 6-month median PFS and 69% DCR vs 2 months/42% for low.
Phase 3 PRISM-MEL-301 trial (brenetafusp + nivolumab) enrolling first-line advanced melanoma patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.